Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 112

Sort by

Sort Order Select

Journal Articles

Characterization of Peripheral Blood Mononuclear Cells Addback Following CD34 Enrichment, Engraftment and T and NK Cells Immune Reconstitution in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Yaya Chu, PhD, Julie-An Talano, MD, Lee Ann Baxter-Lowe, PhD, Carolyn A. Keever-Taylor, PhD, Erin Morris, RN, BSN, Harshini Mahanti, BS, MSCR, Janet Ayello, MS, MT(ASCP), Bryon Johnson, PhD, Rona Singer Weinberg, PhD, Qiuhu Shi, PhD, Theodore B. Moore, MD, Sandra Fabricatore, RN, PNP, MSN, Brenda J. Grossman, MD, Carmella van de Ven, MA, Shalini Shenoy, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-140425

Published: 2020

Journal Articles

Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL)

Jessica C. Hochberg, MD, Stanton Goldman, MD, Matthew J. Barth, MD, Qiuhu Shi, PhD, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Jackie Basso, Yaya Chu, PhD, Humayun Islam, Perry Gerard, MD MBA, FACR, Javier Oesterheld, MD, Kenneth Matthew Heym, MD, Ivan I. Kirov, MD, Richard A. Drachtman, MD, Paul Harker-Murray, MD PhD, Sherrie L. Perkins, MD PhD, Rodney R. Miles, MD PhD, Bruce Shiramizu, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-139464

Published: 2020

Journal Articles

Preliminary Results of a Phase II Study to Determine the Safety of Defibrotide in Children and Adolescents with Sickle Cell Disease-Associated Acute Chest Syndrome (IND 127812)

Jordan Milner, MD, Deborah Friedman, MD, Marise D'Souza, MD MSc, Krishnan Sankaran, MD, Liana Klejmont, Pharm D, Erin Morris, RN, BSN, Harshini Mahanti, BS, MSCR, Neida Otero, Jessica C. Hochberg, MD, Adele Brudnicki, MD, Ken R. Cooke, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-139617

Published: 2020

Journal Articles

Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL)

Yaya Chu, PhD, Susiyan Jiang, MS, Jian Jiang, MD, Meijuan Tian, PhD, Dean Anthony Lee, MD PhD, Loui Madakamutil, Mario Q. Marcondes, MDPhD, Christian Klein, PhD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-139822

Published: 2020

Journal Articles

Rapid Engraftment, Immune Cell Reconstitution and Sustained Donor Chimerism in Patients Receiving G-CSF Mobilized Peripheral Blood Stem Cells (PB-SC) from Related or Unrelated Donors Undergoing CD34 Enrichment with Mononuclear Cell (T cell) Addback in Children, Adolescents, and Adults with Malignant and Nonmalignant Diseases

Jordan Milner, Cydney Nichols, Janet Ayello, MS, MT(ASCP), Karen P. Seiter, MD, Delong Liu, MD PhD, Erin Morris, RN, BSN, Sandra Fabricatore, RN, PNP, MSN, Yaya Chu, PhD, Rosemarie Shaw, Carmella van de Ven, MA, Allyson M. Flower, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-137668

Published: 2020

Journal Articles

Safety and Efficacy of Virus-Specific Cytotoxic T-Lymphocytes Manufactured By the IFN-g Cytokine Capture System for the Treatment of Refractory Adenovirus, Cytomegalovirus, Epstein Barr Virus, and BK Virus Infections in Children, Adolescents and Young Adults after Allogeneic Hematopoietic Stem Cell Transplantation, Solid Organ Transplantation, or with Primary Immunodeficiency (IND# 17449)

Allyson M. Flower, MD, Rachel Friedmann, DO, Janet Ayello, MS, MT(ASCP), Olivia Rigot, PhD, Lauren Harrison, RN, MSN, Erin Morris, RN, BSN, Meghan Sturhahn, RN, MSN, Elana Maryamchik, MD, Yongping Wang, MD, Lynn O'Donnell, PhD, Rolla Abu-Arja, MD, Dean Anthony Lee, MD PhD, Julie-An Talano, MD, Bryon Johnson, PhD, Nancy Bunin, MD, Mitchell S Cairo, MD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-140834

Published: 2020

Journal Articles

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Jessica C. Hochberg, MD, Jaclyn Basso, RN, MSN, PNP, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Allyson M. Flower, MD, Aliza Gardenswartz, MD, Qiuhu Shi, PhD, Perry Gerard, MD MBA, FACR, Humayan Islam, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 127.

https://doi.org/10.1182/blood-2019-128684

Published: 2019

Journal Articles

Sustained Donor Chimerism and Rapid Immune Cell Reconstitution Following Familial Haploidentical (FHI) CD34 Enriched Stem Cell Transplantation with Pbmnc Addback in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Yaya Chu, PhD, Julie-An Talano, MD, Lee Ann Baxter-Lowe, PhD, Carolyn A. Keever-Taylor, PhD, Erin Morris, RN, BSN, Harshini Mahanti, BS, MSCR, Janet Ayello, MS, MT(ASCP), Rona Singer Weinberg, PhD, Qiuhu Shi, PhD, Theodore B. Moore, MD, Sandra Fabricatore, RN, PNP, MSN, Brenda J. Grossman, MD, Carmella van de Ven, MA, Shalini Shenoy, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 1990.

https://doi.org/10.1182/blood-2019-126757

Published: 2019

Journal Articles

A Pilot Study of an Oral Anticoagulant, Apixaban, in Secondary Prophylaxis of Venous Thromboembolism (VTE) in Children and Adolescents

Ashley Pinchinat, MD, Neida Otero, Harshini Mahanti, BS, MSCR, Erin Morris, RN, BSN, Adele Brudnicki, MD, Deborah Friedman, MD, Simon Li, MD, Oya Levendoglu-Tugal, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 2443.

https://doi.org/10.1182/blood-2019-130468

Published: 2019

Journal Articles

Next Generation Sequence Minimal Residual Disease (NGS-MRD) Predicts Outstanding Event Free Survival (EFS) Regardless of Hematopoietic Cell Transplantation (HCT) Preparative Approach or Graft Alpha/Beta Depletion in Children with Acute Lymphoblastic Leukemia (ALL)

Hisham Abdel-Azim, Christopher C. Dvorak, MD, Nancy Bunin, MD, Mark C. Walters, MD, Julie-An Talano, MD, Eric Jon Anderson, MD, Jemily Malvar, MS, May Al Jassani, Sonali Chaudhury, MBBS,MD, Mitchell S Cairo, MD, Carrie Kitko, MD, Allison P. Jacob, Dimitri S. Monos, PhD, Leung Wing, MD PhD, Michael A. Pulsipher, MD

Blood (2019) 134 (Supplement_1): 4624.

https://doi.org/10.1182/blood-2019-131706

Published: 2019

Journal Articles

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

Anthony N. Audino, MD, Matthew J. Barth, MD, Aradhana Tiwari, PhD, Dina Edani, MS, Janet Ayello, MS, MT(ASCP), Lauren Harrison, RN, MSN, Erin Morris, RN, BSN, Jessica C. Hochberg, MD, Stanton Goldman, MD, Christian Klein, PhD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 3963.

https://doi.org/10.1182/blood-2019-128580

Published: 2019

Journal Articles

Upfront Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Jessica C. Hochberg, MD, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Allyson M. Flower, MD, Quihu Shi, PhD, Jaclyn Basso, RN, MSN, PNP, Mitchell S. Cairo, MD

Blood (2017) 130 (Supplement 1): 4094.

https://doi.org/10.1182/blood.V130.Suppl_1.4094.4094

Published: 2017

Journal Articles

Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL)

Yaya Chu, PhD, Nang Kham Su, BS, Sarah Alter, PhD, Emily K Jeng, Peter R Rhode, PhD, Matthew J. Barth, MD, Dean Anthony Lee, MD PhD, Hing C Wong, PhD, Mitchell S. Cairo, MD

Blood (2017) 130 (Supplement 1): 3587.

https://doi.org/10.1182/blood.V130.Suppl_1.3587.3587

Published: 2017

Journal Articles

Mitoxantrone in Combination with Clofarabine (MITCL) in Children, Adolescents and Young Adults with Refractory/Relapsed Acute Leukemia

Jessica C. Hochberg, MD, Javier Oesterheld, MD, Allyson M. Flower, MD, Liana Klejmont, Pharm D, Gregory Hemenway, MS2, Lauren Harrison, RN, MSN, Qiuhu Shi, PhD, Mitchell S. Cairo, MD

Blood (2017) 130 (Supplement 1): 3893.

https://doi.org/10.1182/blood.V130.Suppl_1.3893.3893

Published: 2017

Journal Articles

Promising Results at 1 Year Follow-up Following Familial Haploidentical (FHI) T-Cell Depleted (TCD) with CD34 Enrichment and T-Cell (CD3) Addback Allogeneic Stem Cell Transplantation in Patients with High-Risk Sickle Cell Disease (SCD) (IND 14359)

Julie-An Talano, MD, Theodore B Moore, MD, Carolyn A. Keever-Taylor, DPhil, Shalini Shenoy, MD, Mark C. Walters, MD, Susan K Parsons, MD MRP, Allen J Dozor, MD, Deborah Friedman, MD, Qiuhu Shi, PhD, Suzanne Braniecki, PhD, Brenda J. Grossman, MD, Rona Singer Weinberg, PhD, Elliott Vichinsky, MD, Yaya Chu, PhD, Erin Morris, RN, BSN, Sandra Fabricatore, RN, PNP, MSN, Janet Ayello, MS, MT(ASCP), Lee Ann Baxter-Lowe, PhD, Mitchell S. Cairo, MD

Blood (2017) 130 (Supplement 1): 4602.

https://doi.org/10.1182/blood.V130.Suppl_1.4602.4602

Published: 2017

Journal Articles

Polatuzumab Vedotin Alone or in Combination with Obinutuzumab Synergistically Enhances I n-Vitro Cytotoxicity and Cytokine Release Against CD20+/ CD79b+ Burkitt Lymphoma (BL) /Primary Mediastinal Large B Cell Lymphoma (PMBL)

Aradhana Tiwari, PhD, Dina Edani, MS, Janet Ayello, MS, MT(ASCP), Christian Klein, PhD, Dean Anthony Lee, MD PhD, Mitchell S. Cairo, MD

Blood (2017) 130 (Supplement 1): 1540.

https://doi.org/10.1182/blood.V130.Suppl_1.1540.1540

Published: 2017

Journal Articles

Familial Haploidentical (FHI) Allogeneic Stem Cell Transplantation (AlloSCT) Utilizing CD34 Enrichment and PB MNC Addback in Children and Adolescents with High Risk Sickle Cell Disease (SCD): Rapid Engraftment, Immune Cell Reconstitution, and Sustained Donor Chimerism (IND 14359)

Janet Ayello, MS, Yaya Chu, PhD, Carolyn A. Keever-Taylor, PhD, Julie-An Talano, MD, Rona Weinberg, PhD, Mildred Semidei-Pomlaes, MS, Lee Ann Baxter-Lowe, PhD, Theodore B. Moore, MD, Sandra Fabricatore, MSN,RN, PNP, Shalini Shenoy, MD, Cori M. Abikoff, MD, Mitchell S. Cairo, MD

Blood (2016) 128 (22): 1245.

https://doi.org/10.1182/blood.V128.22.1245.1245

Published: 2016

Journal Articles

A Pilot Trial of Unmatched Human Placenta-Derived Stem Cells (HPDSCs) in Conjunction with Unrelated Cord Blood Transplantation (UCBT) in Children and Young Adults with Malignant and Non-Malignant Disease (IND 14949)

Blood (2016) 128 (22): 4671.

https://doi.org/10.1182/blood.V128.22.4671.4671

Published: 2016

Journal Articles

Microrna (miR)-17-92 Contributes to Therapy Resistance in Burkitt Lymphoma Cells

Rodney R. Miles, MD PhD, Vladimir Rodic, Matthew J. Barth, MD, Mitchell S. Cairo, MD, Michelle L. Hermiston, MD PhD

Blood (2016) 128 (22): 2944.

https://doi.org/10.1182/blood.V128.22.2944.2944

Published: 2016

Journal Articles

Polatuzumab Vedotin; Antibody Drug Conjugates (ADC, anti-CD79b-vc-MMAE, PV) Significantly Enhances in-Vitro Cell Death Against CD79b+ Burkitt Lymphoma (BL) /Primary Mediastinal Large B Cell Lymphoma (PMBL) and Improved Overall Survival Against Rituximab Sensitive/Resistant-BL NSG Xenograft Mice

Aradhana Awasthi, Janet Ayello, MS, Carmella van de Ven, MA, Asana Love, Mitchell S. Cairo, MD

Blood (2016) 128 (22): 4126.

https://doi.org/10.1182/blood.V128.22.4126.4126

Published: 2016

NARROW

Characterization of Peripheral Blood Mononuclear Cells Addback Following CD34 Enrichment, Engraftment and T and NK Cells Immune Reconstitution in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

Final Report of Reduced Anthracycline Dose Intensity with the Addition of Dose Dense Rituximab in Children, Adolescents and Young Adults with De Novo Good Risk Mature B-Cell Non Hodgkin Lymphoma (B-NHL)

Preliminary Results of a Phase II Study to Determine the Safety of Defibrotide in Children and Adolescents with Sickle Cell Disease-Associated Acute Chest Syndrome (IND 127812)

Optimizing Ex-Vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined with NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL)

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Sustained Donor Chimerism and Rapid Immune Cell Reconstitution Following Familial Haploidentical (FHI) CD34 Enriched Stem Cell Transplantation with Pbmnc Addback in Patients with High Risk Sickle Cell Disease (SCD) (IND 14359)

A Pilot Study of an Oral Anticoagulant, Apixaban, in Secondary Prophylaxis of Venous Thromboembolism (VTE) in Children and Adolescents

Next Generation Sequence Minimal Residual Disease (NGS-MRD) Predicts Outstanding Event Free Survival (EFS) Regardless of Hematopoietic Cell Transplantation (HCT) Preparative Approach or Graft Alpha/Beta Depletion in Children with Acute Lymphoblastic Leukemia (ALL)

Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma

Upfront Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL)

Mitoxantrone in Combination with Clofarabine (MITCL) in Children, Adolescents and Young Adults with Refractory/Relapsed Acute Leukemia

Promising Results at 1 Year Follow-up Following Familial Haploidentical (FHI) T-Cell Depleted (TCD) with CD34 Enrichment and T-Cell (CD3) Addback Allogeneic Stem Cell Transplantation in Patients with High-Risk Sickle Cell Disease (SCD) (IND 14359)

Polatuzumab Vedotin Alone or in Combination with Obinutuzumab Synergistically Enhances I n-Vitro Cytotoxicity and Cytokine Release Against CD20+/ CD79b+ Burkitt Lymphoma (BL) /Primary Mediastinal Large B Cell Lymphoma (PMBL)

Familial Haploidentical (FHI) Allogeneic Stem Cell Transplantation (AlloSCT) Utilizing CD34 Enrichment and PB MNC Addback in Children and Adolescents with High Risk Sickle Cell Disease (SCD): Rapid Engraftment, Immune Cell Reconstitution, and Sustained Donor Chimerism (IND 14359)

A Pilot Trial of Unmatched Human Placenta-Derived Stem Cells (HPDSCs) in Conjunction with Unrelated Cord Blood Transplantation (UCBT) in Children and Young Adults with Malignant and Non-Malignant Disease (IND 14949)

Microrna (miR)-17-92 Contributes to Therapy Resistance in Burkitt Lymphoma Cells

Polatuzumab Vedotin; Antibody Drug Conjugates (ADC, anti-CD79b-vc-MMAE, PV) Significantly Enhances in-Vitro Cell Death Against CD79b+ Burkitt Lymphoma (BL) /Primary Mediastinal Large B Cell Lymphoma (PMBL) and Improved Overall Survival Against Rituximab Sensitive/Resistant-BL NSG Xenograft Mice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only